PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis

Cristian Rodriguez‐Aguayo; Emine Bayraktar; Cristina Ivan; Burcu Aslan; Junhua Mai; Guangan He; Lingegowda S. Mangala; Dahai Jiang; Archana S. Nagaraja; Bülent Özpolat; Arturo Chávez‐Reyes; Mauro Ferrari; Rahul Mitra; Zahid H. Siddik; Haifa Shen; Xianbin Yang; Anil K. Sood; Gabriel Lopez‐Berestein

doi:10.1016/j.ebiom.2018.11.045

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

These findings identify PTGER3 as a potential therapeutic target in chemoresistant ovarian cancers expressing high levels of this oncogenic protein. FUND: National Institutes of Health/National Cancer Institute, USA.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rodriguez‐Aguayo et al. (2019) studied this question.

synapsesocial.com/papers/69d7c64a33ca018b39ae2bcf https://doi.org/10.1016/j.ebiom.2018.11.045

View Full Paper

Ask AI

Bookmark

Share

PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis

Ask about this paper

Abstract

Discussion

Cite This Study

PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading